BTIG Reiterates Buy on Coya Therapeutics, Maintains $16 Price Target
Benzinga Newsdesk 1 month ago
Analyst RatingsNewsReiterationPrice Target
BTIG analyst Thomas Shrader reiterates Coya Therapeutics (NASDAQ:COYA) with a Buy and maintains $16 price target.
BTIG analyst Thomas Shrader reiterates Coya Therapeutics (NASDAQ:COYA) with a Buy and maintains $16 price target.